• World Neurosurg · Jan 2025

    A 25 Year Update on the Facial Nerve Sparing Approach for Vestibular Schwannoma.

    • Jonathan A Sisti, Mychael W Delgardo, Nina Yoh, Ogoegbunam B Okolo, Pavan S Upadhyayula, Andrés Pascual-Leone, Catherine R Paccione, WangTony J CTJCDepartment of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA; Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York, USA., and Michael B Sisti.
    • Department of Neurological Surgery, Columbia University Irving Medical Center, New York, New York, USA.
    • World Neurosurg. 2025 Jan 30; 195: 123603123603.

    BackgroundThis study updates the results of a facial nerve preservation approach to treating vestibular schwannomas at a single institution by a single surgeon using retrosigmoid craniectomy with microsurgery (MS) and gamma knife stereotactic radiosurgery (SRS) over a 25-year interval.MethodsWe retrospectively reviewed 751 patients between 1998 and 2023 and grouped them by intervention: MS only (Group 1, 217 patients), SRS only (Group 2, 447 patients), MS then SRS (Group 3, 72 patients), SRS then MS (Group 4, 10 patients), and SRS then SRS (Group 5, 5 patients). The primary outcome variable was facial nerve function, defined as House-Brackmann grade ≤2 at last follow-up.ResultsGood outcomes by group were achieved in 98.2%, 99.6%, 93.1%, 90%, and 100% of patients, respectively. Upfront SRS (Group 2) resulted in significantly better facial nerve outcomes than upfront MS (Groups 1 and 3, 289 patients) (96.9% and 99.4%, P < 0.05). Mean tumor maximum linear diameters were 3.2, 1.32, 3.23, 1.98, and 1.64 cm. Subtotal resection rates in Groups 1, 3, and 4, were 68.2%, 81.9%, and 80%, respectively. The median (interquartile range) follow-up time among patients (minimum follow-up of 12 months) was 52 (26.75-88) months, with a maximum of 297 months (24.75 years). Overall, 98.1% of patients had a good facial nerve outcome with no operative mortality.ConclusionsFor larger tumors, MS emphasizing facial nerve preservation over gross total resection followed by adjuvant SRS for any interval tumor regrowth yields excellent facial nerve outcomes and tumor control rates. For smaller tumors, upfront SRS achieves superior facial nerve preservation with MS and SRS both viable salvage options for treatment of tumor progression. This paradigm balances tumor control, facial nerve preservation, and low morbidity.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…